Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Sells $4,444,750.00 in Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Suma Krishnan also recently made the following trade(s):

• On Friday, December 13th, Suma Krishnan sold 25,000 shares of Krystal Biotech stock. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00.

Krystal Biotech Stock Performance

NASDAQ KRYS traded down $1.02 during trading hours on Thursday, hitting $177.37. 262,590 shares of the company’s stock were exchanged, compared to its average volume of 289,967. The business’s 50 day moving average is $162.66 and its 200-day moving average is $174.19. Krystal Biotech, Inc. has a 12-month low of $141.72 and a 12-month high of $219.34. The firm has a market capitalization of $5.11 billion, a P/E ratio of 59.32 and a beta of 0.87.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.23. The firm had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm’s revenue for the quarter was up 116.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.30 earnings per share. As a group, equities research analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on KRYS shares. HC Wainwright restated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Friday, February 28th. Jefferies Financial Group started coverage on Krystal Biotech in a research report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price objective on the stock. Chardan Capital upped their price objective on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research report on Thursday, February 20th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, Citigroup upped their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $220.00.

Hedge Funds Weigh In On Krystal Biotech

A number of large investors have recently modified their holdings of KRYS. Norges Bank purchased a new position in shares of Krystal Biotech in the 4th quarter worth about $34,391,000. Soleus Capital Management L.P. raised its holdings in shares of Krystal Biotech by 65.2% in the 4th quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company’s stock worth $56,144,000 after purchasing an additional 141,400 shares during the period. Segall Bryant & Hamill LLC raised its holdings in shares of Krystal Biotech by 352.4% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock worth $28,605,000 after purchasing an additional 122,407 shares during the period. State Street Corp raised its holdings in shares of Krystal Biotech by 9.0% in the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after purchasing an additional 119,936 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in shares of Krystal Biotech in the 4th quarter worth about $15,989,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).